These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4736493)

  • 1. Levodopa and dopamine in cerebrospinal fluid.
    Papavasiliou PS; Cotzias GC; Lawrence WH
    Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson disease treated with a suspected dopamine receptor agonist.
    Chase TN; Woods AC; Glaubiger GA
    Arch Neurol; 1974 May; 30(5):383-6. PubMed ID: 4821783
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
    Tohgi H; Ogawa M
    No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 6. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM; Wiener L
    Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract]   [Full Text] [Related]  

  • 9. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD; Barry PE; Parkes JD; Zilkha KJ
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
    Muenter MD; Dinapoli RP; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 13. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 14. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

  • 15. [Attempt at treating parkinsonism with L-dopa and Artane].
    Stelmasiak Z; Lackowska H; Maksymowicz B
    Pol Tyg Lek; 1971 Aug; 26(34):1325-6. PubMed ID: 5110789
    [No Abstract]   [Full Text] [Related]  

  • 16. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
    Holden EM; Brody JA; Chase TN
    Neurology; 1974 Mar; 24(3):263-5. PubMed ID: 4855953
    [No Abstract]   [Full Text] [Related]  

  • 18. Permanent dementia in idiopathic Parkinsonism treated with levodopa.
    Wolf SM; Davis RL
    Arch Neurol; 1973 Oct; 29(4):276-8. PubMed ID: 4728189
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

  • 20. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.